The Phia Group Blog

By: Bryan M. Dunton, Esq. Prescription drug costs remain one of the most visible challenges for employer-sponsored health plans and the employees who rely on them. Over the past several years, policymakers have increasingly focused on pharmacy benefit managers (PBMs),…

By: David Ostrowsky Though the No Surprises Act (NSA) was designed to safeguard patients against receiving unexpected medical bills, it has become apparent that certain trends within the corresponding Independent Dispute Resolution (IDR) process may be contributing to increased costs…

By: Kate MacDonald For decades, American students have learned about the value of the food pyramid in schools, sitting in their health class, listening to lectures about how proper portion control and a sensible diet can lead to good health….

By: David Ostrowsky On the prescription drug front, the recent launch of TrumpRx has been all the rage on the federal level, but not to be overlooked, there have been some fascinating state-specific developments worth examining. In Connecticut, a new…

By: Naga Vivekanandan, Esq. Medicare has spent years watching GLP-1 drugs move from a promising diabetes therapy to one of the most consequential drivers of prescription drug spending. That shift has been fueled by strong clinical results, expanding indications, and…

By: David Ostrowsky For some Americans, there is a natural tendency to conflate healthcare with health insurance. Perhaps on the surface, they seem one and the same, but in reality, of course, they are entirely different entities: the former involves…